Initially discovered in melanoma, BRAF mutations have since been identified across a wide spectrum of malignancies, including non-small-cell lung cancer (NSCLC), colorectal cancer (CRC), thyroid cancer, gliomas, other rare cancers, and various hematologic and pediatric tumors. Here, BRAF is linked to thyroid cancer.